Profiles

Keywords
Last Name
Institution

Connection

Search Results to Timothy Kuzel

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Kuzel, Timothy

Item TypeName
Concept Drug Administration Schedule
Academic Article A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
Academic Article Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial.
Academic Article Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
Academic Article Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group.
Academic Article Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Academic Article A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
Academic Article Systemic chemotherapy for the treatment of mycosis fungoides and Sézary syndrome.
Academic Article A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
Academic Article Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome.
Academic Article Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Academic Article Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Academic Article Acute generalized exanthematous pustulosis in a patient receiving high-dose recombinant interleukin-2.
Academic Article Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Academic Article Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Search Criteria
  • Drug Administration Schedule